New Zealand markets closed
  • NZX 50

    11,214.49
    -220.33 (-1.93%)
     
  • NZD/USD

    0.5684
    +0.0046 (+0.81%)
     
  • NZD/EUR

    0.5895
    +0.0034 (+0.57%)
     
  • ALL ORDS

    6,683.20
    +15.70 (+0.24%)
     
  • ASX 200

    6,485.90
    +16.50 (+0.26%)
     
  • OIL

    77.20
    +0.49 (+0.64%)
     
  • GOLD

    1,638.50
    +5.10 (+0.31%)
     
  • NASDAQ

    11,254.11
    -57.13 (-0.51%)
     
  • FTSE

    7,020.95
    +2.35 (+0.03%)
     
  • Dow Jones

    29,260.81
    -329.60 (-1.11%)
     
  • DAX

    12,227.92
    -56.27 (-0.46%)
     
  • Hang Seng

    17,665.85
    -189.29 (-1.06%)
     
  • NIKKEI 225

    26,565.96
    +134.41 (+0.51%)
     
  • NZD/JPY

    82.0840
    +0.5550 (+0.68%)
     

Even after rising 38% this past week, Agios Pharmaceuticals (NASDAQ:AGIO) shareholders are still down 49% over the past five years

·3-min read

It is a pleasure to report that the Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is up 46% in the last quarter. But that doesn't change the fact that the returns over the last five years have been less than pleasing. You would have done a lot better buying an index fund, since the stock has dropped 49% in that half decade.

While the last five years has been tough for Agios Pharmaceuticals shareholders, this past week has shown signs of promise. So let's look at the longer term fundamentals and see if they've been the driver of the negative returns.

See our latest analysis for Agios Pharmaceuticals

Because Agios Pharmaceuticals made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

In the last five years Agios Pharmaceuticals saw its revenue shrink by 16% per year. That's definitely a weaker result than most pre-profit companies report. On the face of it we'd posit the share price fall of 8% compound, over five years is well justified by the fundamental deterioration. This loss means the stock shareholders are probably pretty annoyed. Risk averse investors probably wouldn't like this one much.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

earnings-and-revenue-growth
earnings-and-revenue-growth

If you are thinking of buying or selling Agios Pharmaceuticals stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

We regret to report that Agios Pharmaceuticals shareholders are down 35% for the year. Unfortunately, that's worse than the broader market decline of 12%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 8% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. It's always interesting to track share price performance over the longer term. But to understand Agios Pharmaceuticals better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Agios Pharmaceuticals , and understanding them should be part of your investment process.

Of course Agios Pharmaceuticals may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here